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Abstract 
Magnetic resonance imaging (MRI) is a powerful non-invasive medical diagnostic 
technique.  Superparamagnetic iron oxide nanoparticles (SPIO) are effective contrast 
agents and provide high sensitivity contrast in MRI.  Recent research has demonstrated 
that nanoparticle clusters exhibit significantly higher relaxivity than individual 
nanoparticles.  
In order to increase the sensitivity of tumor imaging, supramolecular chemistry 
was introduced to this field and a novel conjugation method was developed using click 
chemistry between azide functionalized nanoparticles and pH-sensitive hydrogen bonding 
building blocks. This pH-sensitive hydrogen bonded complex was synthesized to cluster 
nanoparticles under mildly acidic biological conditions.   
Due to the unexpected X-ray crystal structure of the acceptor molecule, erroneous 
results were obtained. An association constant (Ka) was determined via 1H NMR titration 
of a similar hydrogen bonding system and the resulting value of 194 M-1 in DMSO. This 
result indicates the potential feasibility of this project. The synthesis, characterization, 
and tests of functionalized SPIO and monomers are reported. 
 
 
 
Keywords 
MRI, SPIO, Contrast agent, Click chemistry, Hydrogen Bond, Supramolecular Polymer.  
 
 	   iv	  
Acknowledgements 
 First and foremost, I would like to thank my supervisors, Dr. James Wisner and 
Dr. Elizabeth Gillies, for providing me with an opportunity to pursue my master studies, 
and their guidance through the past two and a half years. I want to thank them for their 
constant support and guidance while undertaking this project.  Their encouragement has 
caused me to strive to be a better student and scientist throughout my time here. 
 I would also like to thank all of the past and present Wisner’s and Gillies’ group 
members. I greatly appreciate my lab mates for providing a friendly atmosphere. Besides 
passing on the techniques.  
 I offer my regards to all of those (Secretaries in chemistry department, Staff in 
ChemBioStore, mass spectrometry, NMR, X-ray analysis) who supported me in any 
respect during my M.Sc. study and research.  
 Lastly, I would like to thank my family and friends in Saudi Arabia and Canada 
for their constant love and support.	  Last but not least, I thank God for giving me the 
determination and strength to pursue my goals. 
 
 
 
 
 
 
 
 
 	   v	  
Table of Contents 
Page 
CERTIFICATE OF EXAMINATION                ii 
ABSTRACT                  iii 
ACKNOWLEDGEMENTS                iv 
TABLE OF CONTENTS                 v 
LIST OF SCHEMES                vii 
LIST OF FIGURES               viii 
LIST OF ABBREVIATIONS                 x 
Chapter 1: Introduction                  1 
 1.1 Supramolecular Polymers                            3 
  1.1.1 Hydrogen bonding in supramolecular chemistry            3
   1.1.2 Factors affecting the strength of hydrogen bonding            4 
   1.1.2.1 Numbers of Hydrogen Bonds                                              4 
   1.1.2.2  Secondary interactions                                                       5 
   1.1.2.3 Acidity and basicity of the donor and acceptor                   8  
   1.1.2.4 Solvents                                                          10  
 1.2 Magnetic Resonance Imaging                                                                          13 
  1.2.1 .MRI and Tumour imaging                                                               13  
  1.2.2. MRI Principles                                                                                 13 
  1.2.3. Paramagnetic Contrast Agents                                                         15 
  1.2.4 Superparamagnetic iron oxide nanoparticles (SPIO) as contrast 
agents                                                                            13  
 	   vi	  
  1.2.5 Targeted iron oxide nanoparticles            16 
 1.3 The Proposal                 18 
  1.3.1 The design                20 
Chapter 2: Results and Discussion                22 
 2.1. Synthesis                            23 
  2.1.1 Synthesis of Donor Molecule             23 
  2.1.2 Synthesis of Acceptor Molecule.                       25  
  2.1.3 Synthesis of Dextran Coated SPIO             29 
  2.1.4 Synthesis of the linker                                              31 
  2.1.5 Conjugating Donor and Acceptor to Nanoparticles           32 
  2.1.6 Synthesis of Donor and Acceptor Monomers            36 
 2.2. pKa Titrations                38 
 2.3. The Affect of Changing pH on the Aggregation of the Nanoparticles          41 
 2.4. X-ray crystallography                42 
 2.5. 1H NMR Titration                44 
Chapter 3: Conclusions and Future Work              45 
Chapter 4: Experimental                48 
 4.1 General Procedures and Materials             49 
4.2 Experimental Section               50 
Chapter 5: References                 66 
Curriculum Vitae                 71
           
 	   vii	  
List of Schemes	  
Scheme 1: Hydrogen bonding between two electronegative atoms D and A mediated by a 
hydrogen atom, H.                    3 
Scheme 2: Synthesis of the donor molecule.              23 
Scheme 3: Synthesis of 6.                 25 
Scheme 4: Synthesis of 8.                 26 
Scheme 5: Synthesis of 12.                 26 
Scheme 6: Synthesis of 13.                 27 
Scheme 7: Synthesis of the acceptor molecule, 14.             28 
Scheme 8: Synthesis of dextran-coated Fe3O4 nanoparticles.            29 
Scheme 9: Synthesis of the linker.                31 
Scheme 10: Synthesis of the functionalized nanoparticles.             32 
Scheme 11: Synthesis of the PEG derivative.              36 
Scheme 12: Synthesis of the donor, 26 and Acceptor, 27 monomers.           37 
 Scheme 13: synthesizing 2,6-diaminopyridin-1-ium chloride.            38 
Scheme 14: synthesis of the acceptor               43 
Scheme 15: suggested future work               47
      
 
 
 
 
 
 
 
 
 	   viii	  
List of Figures 
Figure 1: increasing the Ka value with an increase of the number of hydrogen bonds.     5 
Figure 2: Secondary interactions based on the sequences of donors and acceptors in 
triply hydrogen bonded complexes.                 6 
Figure 3: Ka values of triply hydrogen-bonded complexes in CDCl3.            6 
Figure 4: an AAAA–DDDD quadruple hydrogen-bond complex.             7 
Figure 5: the effect of substituents on the association constant.              8 
Figure 6: the effect of charges on the association constant.               9 
Figure 7: The intended 2:1 donor: acceptor complex and the resulting 1:1 complex 
observed in the solid state.                 12 
Figure 8: The x-ray crystal structure of the 1:1 complex. Primary hydrogen bonds and π-
π stacking interactions are evident in the structure.                12 
Figure 9: positive contrast agents and negative contrast agents images of coronal brain 
slices of mice infected with T. gondii.                                      15 
Figure 10: The primary and secondary interactions that are expected for the target 
complex.                   18 
Figure 11: clicking donor and acceptor molecules to SPIO nanoparticles.           20 
Figure 12: clicking donor and acceptor molecules to a bifinctional monomer.          21 
Figure 13: Size distrubution of nanoparticles 15 and 16             30 
Figure 14: UV-Vis absorbance of nanoparticles 15 and 16            30 
Figure 15: UV-Vis absorbance of nanoparticles 16 in pH 7.4 aqueous buffer and 21     33 
Figure 16: Size distrubution of nanoparticles 21.               34 
Figure 17: Infrared spectra illustrating changes on nanoparticle surface.          34 
Figure 18: Size distrubution of nanoparticles 22 and 23                             35 
Figure 19: Weak acid-strong base titration of 2,6-diaminopyridinium chloride.          39  
Figure 20: Weak acid-strong base titration of 26 HCl salt.             40 
Figure 21: Z-average size changing with pH.                          41 
 	   ix	  
Figure 22: X-ray crystal structure of 14.               42 
Figure 23: Titration curves for complex G.               44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
 	   x	  
List of Abbreviations 
 
A    acceptor  
AT   adenine-thymine  
oC                               degrees celsius  
CG              cytosine-guanine 
δ                                  chemical shift 
D                                 donor  
DCC              dicyclohexylcarbodiimide 
DLS               dynamic light scattering 
DMF              N,N-dimethylformamide 
DMF                           dimethylformamide 
DMSO                        dimethylsulfoxide  
DNA              deoxyribonucleic acid 
ESI                               electrospray ionization 
EDTA               ethylenediaminetetraacetic acid  
g                                   gram 
∆G                               change in Gibbs free energy 
h                                   hour 
Hz                                 hertz 
IR   infrared spectroscopy 
Ka   association constant 
kJ                                 kilo Joule 
m                                 multiplet 
M-1                              (mol/liter)-1 
mCPBA                      metachloroperoxybenzoic acid 
 	   xi	  
min                              minute 
mL                               milliliter 
mmol                           millimole  
mol-1               /mol 
m.p.               melting point 
MRI              magnetic resonance imaging  
MWCO  molecular weight cutoff  
NMR   nuclear magnetic resonance  
RF   radio frequency  
SPIO   superparamagnetic iron oxides 
TBAF   tetrabutylammonium fluoride  
THF   tetrahydrofuran 
TMSA   trimethylsilylacetylene  
 	   1	  
 
  
 
 
 
 
 
Chapter 1: Introduction 
 
 
 
 
 
 
 
 	   2	  
The hydrogen bonding and π stacking interactions between natural 
complementary DNA nucleobases, adenine-thymine (A-T) and guanine-cytosine (G-C), 
are responsible for the stabilization of the double helical DNA structure and contribute to 
its central biological processes of transcription and replication. These examples provide 
an inspiration to use heteroaromatic building blocks to build molecules that can interact 
through hydrogen bonding and π-π stacking to self-assemble and form new non-
traditional supramolecular polymers.1  
Unlike classical polymers where individual building blocks are connected by 
covalent bonds, supramolecular polymers are held together by non-covalent interactions. 
These non-covalent bonds are weaker than covalent bonds and reversible, which give 
supramolecular polymers switchable properties. As a result, supramolecular polymers are 
affected by their surrounding environment such as temperature, polarity of the solvent, or 
pH.2,3  
Inspired by a pH switchable supramolecular polymer, the idea of using such a 
system to signal the presence of tumours due to differences in pH between normal and 
cancerous tissues have been brought to light.3 Thus, the design of a recognition system 
that capitalizes on pH dependent recognition could be used to increase the sensitivity of 
tumor imaging. Herein, we describe the elaboration of a pH dependent recognition motif 
that may be combined with iron oxide nanoparticles and used as contrast agent in 
magnetic resonance imaging (MRI) in an attempt to improve the sensitivity of tumour 
imaging. 
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1.1 Supramolecular Polymers 
The non-covalent interactions between building blocks of supramolecular 
polymers such as electrostatic interactions, coordination bonds, hydrogen bonding, π-π 
interactions, van der Waals forces and hydrophobic effects are the key to control the 
supramolecular polymer formation through molecular recognition and self-organization.  
1.1.1 Hydrogen bonding in supramolecular chemistry 
A hydrogen bond is an interaction between a hydrogen atom (donor) and an 
electronegative atom, such as nitrogen or oxygen (acceptor). The hydrogen atom is 
usually covalently bonded to another more electronegative atom such as O, N, S, F, Cl, 
Br or I causing the hydrogen atom to obtain a significant amount of positive charge. The 
strength of the hydrogen bond is dependent on the dipole moment of the donor, the 
negative charge on the acceptor and the angle of interaction. The strength of hydrogen 
bonds is usually in the range of 20‐25 kJ/mol, but it can reach as high as 160 kJ/mol in 
F-H…Fˉ. Typically three atoms (D-H…A) are arranged with an ideal angle (θ) close to 
180°. 
 
 
Scheme 1: Hydrogen bonding between two electronegative atoms D and A mediated by a 
hydrogen atom, H. 
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1.1.2 Factors affecting the strength of hydrogen bonding  
The hydrogen bonding strength and stability in these self-assembled molecules depends 
on many factors such as numbers of hydrogen bonds, secondary interactions, the acidity 
of the donors and the basicity of the acceptor atoms and solvents. The measurement of 
the binding strength is called the association constant (Ka), which is the mathematical 
constant that describes the affinity of two molecules at equilibrium: 
 
 
  1.1.2.1 Numbers of Hydrogen Bonds 
A positive relationship is observed between the number of hydrogen bonds and the 
stability of resulting complexes (Figure 1).4  The increase in stability is due to the increase 
of the binding energy that is based on the increase of the number of hydrogen bonds. This 
relationship is observed in the differences in the association constant between the G-C 
base pair and the A-T base pair. Since the G-C base pair has three hydrogen bonds while 
the A-T base pair has two hydrogen bonds, the association constant and the stability of 
the G-C base pair (Ka = 104-105 M-1 in CDCl3) is greater than the A-T base pair (Ka = 102 
M-1 in CDCl3).5 Based on this observation, a complex consisting of four hydrogen bonds 
will have a higher association constant than the DNA base pairs. A Ka value of 3 x 107 M-
1 was measured for a DAAD.ADDA complex that Zimmerman and coworkers 
synthesized.1  
D H A D H A Ka =
D H A
D HA
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Figure 1: Increasing Ka value with an increase in the number of hydrogen bonds.  
 
1.1.2.2  Secondary interactions 
The stability of a complex may be determined not only by the number of hydrogen bonds, 
but also the arrangement of the hydrogen bond donor and acceptor sites in the two 
molecules forming the complex (Figure 2). In 1990, a study was performed by Jorgenson 
and Pranata to illustrate the effect of the secondary interactions in DNA-like triply 
hydrogen bonded complexes. They found that the strength and the stability of the 
complexes have a positive relationship with the number of attractive secondary 
electrostatic interaction between donors and acceptors atoms and an inverse relationship 
with secondary repulsion between them.1,6 As a result, an AAA-DDD complex will have 
more stability and strength than an ADA-DAD or an AAD-DDA complex because it has 
another two-four attractive secondary hydrogen bonds beside the primary hydrogen 
bonds and no repulsive secondary interactions.  
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Figure 2: Secondary interactions based on the sequences of donors and acceptors in 
triply hydrogen bonded complexes. 
For example, complex A has a Ka value >105 M-1 in CDCl3 (Figure 3).7  In 
comparison, the AAD-DDA complex has two attractive secondary hydrogen bonds and 
two repulsive secondary interactions and because of that it has a lower Ka value than 
complex B (Ka= 104-105 M-1). 6 Finally, the ADA-DAD complex with four repulsive 
secondary interactions has the lowest Ka value for triply hydrogen bonded complexes 
(complex C with Ka = 78 M-1).1 
 
 
 
 
 
 
Figure 3: Ka values of triply hydrogen-bonded complexes in CDCl3. 
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In 2011, Leigh and coworkers combined the effect of both hydrogen bond number 
and the secondary interactions to synthesize complex D, which contains an AAAA–
DDDD quadruple hydrogen-bond complex that has an extremely high Ka value in non-
polar solvents (Figure 4).8 
 
 
 
 
 
 
Figure 4: an AAAA–DDDD quadruple hydrogen-bond complex.  
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1.1.2.3  Acidity and basicity of the donor and acceptor  
The individual or primary hydrogen bond strength is affected by the acidity of the donor 
and basicity of the acceptor. Applying that to a multiple hydrogen bonding complex, we 
can determine the strength and stability based on the expecting the pKa values and 
altering it by changing the functional groups on the complex.1 In 1966, Yoshimasa and 
coworkers investigated the effect of substituents of the hydrogen bonding of adenine and 
uracil derivatives on the association constants of their complexes (Figure 5). Their study 
indicated the role substituents might play to enhance or decrease the strength of the 
adenine-uracil association.  
 
Figure 5: The effect of substituents on the association constant. 
 
First, the loss of aromaticity because of the hydrogenation in 5,6-dihydrouracil is 
responsible for the increase of the Ka value in complex E2 than E1. The resonance in 
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complex E2 gives the 4-carbonyl oxygen atom more electron density and more basicity 
as a result. In addition, the pKa of the amide group increased from 9.4 in uracil to 11 or 
larger in E2. Secondly, adding a methyl group to uracil in complex E3 increased the 
association complex. This increase is due to the role of the methyl group as an electron 
donor which increased further the basicity of the 4-carbonyl oxygen and increased the 
pKa value of the amide group from 9.4 to 9.9.9 
 Moreover, having appropriate charge in the complex will increase stability.1 We 
can see the huge increase in strength that a complex gains from the Ka value of complex 
F, (Ka = 3 X 1010 M-1 in CH2Cl2) because the positive charge in the cationic DDD 
enhances the hydrogen bond donor character and gives electrostatic stabilization to the 
complex.10 
 
 
 
 
 
Figure 6: the effect of charge on the association constant. 
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1.1.2.4  Solvents  
Another important factor that affects the strength and stability of hydrogen bonded 
complexes is the solvent. Generally, there is an inverse relationship between solvent 
polarity and hydrogen bonding strength. Less polar solvents such as hydrocarbons 
increase the strength while protic or polar solvents such as water or DMSO decrease it.1 
Therefore most hydrogen bonded supramolecular complexes are characterized in 
chloroform or toluene, but unfortunately the solubilities of some donors or acceptors are 
poor in these solvents and this can cause complications. In 2007, Hunter and his 
coworkers studied the effects of different solvents on the association constants for 
formation of a 1:1 complex between tri-n-butylphosphine oxide and perfluoro-tert-butyl 
alcohol at 295 K. The results in the table below illustrates the higher association constants 
in CCl4 and cyclohexane over DMSO and other polar solvents due to lack of competition 
with the hydrogen bonds of the complex.11 
 
 
Solvents Association constants (Ka in M-1) 
DMSO 6.8 x10-1 
Acetone 6.5 x10-1 
Acetonitrile 1.6 x102 
Tetrahydrofuran 2.4 x102 
CHCl3 2.7 x103 
CCl4 7.6 x104 
Cyclohexane >105 
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In another study, Rehm and Schmuck reported many solutions to increase the 
strength of self-assembly in polar solvents based on previous research and their own 
research because most hydrogen bond assemblies are not stable enough to be useful in 
polar protic solvents on their own. 2 First, using strong metal–ligand interactions in 
addition to hydrogen bonds gives the hydrogen bond-mediated assembly stability in 
water because a coordination bond between the metal and the ligand can be as stable as a 
covalent bond. On the other hand, this technique can have disadvantages such as toxicity 
and high cost. Ion-pair formation is the second solution because the electrostatic 
interaction is more stable than hydrogen bonding but not as much as the coordinate bond 
in metal–ligand interaction and this charge interaction beside hydrogen bonding is very 
important for the stability of a self- assembly in polar protic solvents. Finally, adding 
functional groups that have an additional electron-donor or acceptor to the monomer 
contributes with the other methods to form a stable and strong self-assembly in polar 
protic solvents.2 
However, these solutions may still not work in polar protic solvents if we employ 
only individual complexes. Multivalency of many of the same groups on the surface of a 
nanoparticle will also contribute to the stability of an aggregate by increasing the number 
of recognition events.  
In recent work performed in the Wisner group, a complex between 2,6- 
diaminopyridinium tetraphenylborate and 1,2-bis(5,7-dimethyl-1,8-naphthyridin-2-
yl)diazene was synthesized. The original intention was a 2:1 complex where the acceptor 
molecule binds to two triple donor molecules (Figure 7, left). However, after obtaining 
the X-ray crystal structure, they found that one of the naphthyridine rings flipped over 
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and formed a 1:1 complex with four primary hydrogen bonds (Figure 7, right). 
 
 
 
 
Figure 7: The intended 2:1 donor: acceptor complex (left) and the resulting 1:1 complex 
(right) observed in the solid state. 
The crystal was obtained from acetonitrile and isopropyl ether, and there are four primary 
hydrogen bonds. In addition, there are π-π stacking interactions between the planar 
complexes (Figure 8).12 Based on the previously reported complex F, and because of the 
extra hydrogen bond this complex should have Ka >> 3 X 1010 M-1 in chlorinated 
solvents. 
 
 
 
 
Figure 8: The x-ray crystal structure of the 1:1 complex.12 Primary hydrogen bonds (left) 
and π-π stacking interactions (right ) are evident in the structure. 
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1.2 Magnetic Resonance Imaging (MRI) 
1.2.1 MRI and Tumour imaging 
In another important field, scientists continually attempt to find the best techniques for 
clinical diagnosis in order to help them differentiate between normal and diseased tissue 
without having to perform surgery to elucidate a patient’s illness. Since the invention of 
Magnetic Resonance Imaging (MRI), many contrast agents have been used to change the 
relaxation times of protons in water molecules in order to better distinguish between 
normal and diseased tissue. MRI has been used for cancer imaging for many years, 13 as 
cancer is one of the leading causes of death. While most previously developed contrast 
agents distinguish tumors from normal tissue on the basis of their leaky vasculature, there 
is a potential for tumor imaging based on the fact that differences in pH exist between 
normal tissues and the blood stream which are around 7-7.4 and between tumors which 
are more acidic where the pH can reach 6 in the extracellular core of the tumor.14 
1.2.2. MRI Principles 
The principles of MRI are similar to those of Nuclear Magnetic Resonance (NMR) 
spectroscopy and depend on the density of protons in the targeted area and the degree of 
polarization of the nuclear spin states.15 When placed in a strong magnetic field (B0), 
proton nuclei, which have a non-zero magnetic moment, will orient either anti-parallel 
(high energy state) with the main magnetic field (B0) or parallel (low energy state) with a 
slight majority reaching a thermal equilibrium, and a precessional motion about B0 at 
some frequency. This slight excess of spins in the low energy state will form a net 
magnetization aligned parallel with B0. A radiofrequency (RF) coil has two important 
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jobs in MRI. First, excitement of the proton nuclei occurs in response to a radiofrequency 
(RF) pulse from this coil, which creates a new magnetic field (B1). The RF pulse affects 
the orientation of the proton nuclei, causing tipping of the overall net magnetization 
toward the transverse plane, which is perpendicular to the main magnetic field (B0). This 
tipping is due to transition of some spins from the low energy state to high energy state 
after absorbing energy from the RF. Also, the spins become phase coherent in the 
transverse plane. In order to begin detecting MR signals, the RF pulse will be turned off 
allowing nuclei to return into their original states (before performing a radiofrequency 
(RF) pulse). These MR signals that are caused from the oscillation of the protons 
translate into electrical current in the same radiofrequency (RF) coil creating the MR 
signal.16 
There are two relaxation mechanisms depending on how the nuclei return to their 
original states. T1 and T2 are relaxation times corresponding to longitudinal and 
transverse relaxation mechanisms. T1 is defined by the time that a radiofrequency excited 
proton in (B1) magnetic field takes to return to the main magnetic field (B0) or to the 
longitudinal axis after turning off the RF pulse. T2 corresponds to the decay of the proton 
around the transverse axis (B0) after losing phase coherence.15 The differences in water 
concentration and environment between healthy and diseased tissues give inherent 
differences in T1 and T2 relaxation times. For example, since the water concentration is 
higher in cancerous tissue than the normal tissue, the T2 values for them are different, 
0.043 seconds for normal and 0.056 seconds for cancerous tissue, and they exhibit 
different T1 values as well.16 
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1.2.3. Paramagnetic Contrast Agents 
The using of paramagnetic contrast agents has rendered MRI one of the most important 
medical imaging techniques currently developed because of the advantages of these 
paramagnetic contrast agents comparing to those for other imaging modalities. For 
example, they do not emit ionizing radiation. They are not visualized directly but rather 
affect the relaxation of water and fat protons in their surrounding areas.17 There are two 
main types of paramagnetic contrast agents that are clinically used based on their effect 
on T1 or T2 relaxation times. First, gadolinium contrast agents affect T1 relaxation times 
more strongly and are called positive contrast agents because they lead to increases in the 
MRI signal intensity under most pulse sequences. Second, superparamagnetic iron oxide 
nanoparticles alter T2 relaxation times more strongly and they are called negative contrast 
agents. They lead to decreases in the MRI signal intensity, often called signal voids in 
their vicinity. 
 
 
 
 
Figure 9: Positive contrast agents (left two images) and negative contrast agents (right 
two images) images of coronal brain slices of mice infected with T. gondii.18 
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1.2.4 Superparamagnetic iron oxide nanoparticles (SPIO) as contrast agents 
The emergence of superparamagnetic iron oxide nanoparticles was very important to 
avoid some disadvantages such as short retention time in vivo, toxicity and 
biocompatibility of other contrast agents like gadolinium.13 Another advantage of iron 
oxide nanopaticles is their sensitivity and they present inhomogenities in the magnetic 
field causing a decrease in T2 relaxation times of healthy tissue. This decrease generates a 
big difference in T2 relaxation time between normal and diseased tissues and, as a result, 
the differences in the signal between them.16,19 In order to allow these nanoparticles to 
work in cells, iron oxide nanoparticles are coated by water soluble polymers such as 
dextran to render them soluble in aqueous or biological media and also to make a 
colloidal suspension more stable.20 Iron oxide nanoparticles were functionalized with 
azide groups and further derivatized using click chemistry.19 This method facilitates the 
conjugation of the nanoparticles to any active targeting group for many applications in 
MRI. 
1.5 Targeted iron oxide nanoparticles 
 One of the important uses of the iron oxide nanoparticles is targeting specific 
areas in the body by taking advantage of in vivo macrophages or attaching specific 
targeting groups to the surface of the nanoparticle. First of all, iron oxide nanoparticles 
can be used to image the liver and spleen due the natural uptake of the nanoparticles by 
macrophages, which work as non-specific defenses against any foreign material.21 
Despite the benefit of macrophages in imaging, it makes it difficult to image any other 
areas in the body. Thus, attaching specific targeting groups on the surface of the 
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nanoparticles is a highly desirable goal. The size of the nanoparticles should be less than 
100 nm to increase the prolonged circulation in the blood stream and avoid non-specific 
uptake by macrophages. There are many examples of attaching peptides, antibodies and 
small molecules to the surface of nanoparticles. As an example of attaching peptides, in 
2005, glioma brain tumors were detectable by both MRI and fluorescence imaging. This 
detection was enabled by attaching chlorotoxin and Cy5.5 to coated iron oxide 
nanoparticles with covalently bound bifunctional poly(ethylene glycol) (PEG). 
Chlorotoxin peptide has a high affinity for the membrane-bound matrix 
metalloproteinase-2 endopeptidases that are found in gliomas, medulloblastomas, the 
neuroectodermal origin tumors.22 Secondly, in the area of using antibodies, having a 
prostate-specific membrane antigen mostly on the neovasculature of solid tumors and on 
the surface of prostate cells helped to develop biotinylated anti-PSMA iron oxide 
nanoparticles that improve the magnetic resonance detection of prostate cancer cells.23 
Finally, folic acid was conjugated to superparamagnetic iron oxide nanoparticles coated 
by covalently bound bifunctional PEG. It is known that the folate receptor is 
overexpressed on the surfaces of many human tumor cells such as ovarian, lung, breast, 
endometrial, renal, and colon cancers. This conjugation of folic acid on the nanoparticles 
results in a significant uptake by target cells in comparison with nanoparticles coated with 
PEG or dextran alone.24 Thus, in order to target specific areas for in vivo imaging, 
attaching active targeting groups on the surface of SPIO is essential to achieve this goal. 
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1.3 The Proposal 
This project combines the two described important fields above. It involves the synthesis 
of a pH-sensitive hydrogen bonded complex and its attachment to iron oxide 
nanoparticles by click chemistry in order to increase the sensitivity of these nanoparticles 
for tumor imaging. This increased sensitivity will be achieved because the hydrogen 
bonding moieties will be designed to assemble selectively at the mildly acidic pH of 
tumor tissue. This bonding is anticipated to induce clustering of the nanoparticles. It has 
been previously demonstrated that nanoparticle clusters exhibit significantly higher 
relaxivity than individual nanoparticles.25 Therefore, the ability to detect the tumor will be 
enhanced by this selective clustering in tumor tissue. Based on the requirement for 
hydrogen bonding induced by mildly acidic pH and previous reports on hydrogen 
bonding moieties,10,12 the monomers were chosen (Figure 10). The hydrogen bonding 
monomers are 3-ethynylpyridine-2,6-diamine (donor molecule) and (E)-7-((5-
ethynylpyridin-2-yl)diazenyl)-2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4-methyl-1,8-
naphthyridine (acceptor molecule).  
 
 
 
 
Figure 10: The primary and secondary interactions that are expected for the target 
complex. 
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The pKa value of the donor molecule was measured by weak acid-strong base titration 
and it was found to be 6.5.  
 
 
 
This value means that under pH 6.5 there will be more protonated molecule, 2,6-diamino-
3-ethynylpyridin-1-ium than 3-ethynylpyridine-2,6-diamine. The formation of this cation 
and having more of it within this region should enhance assembly by hydrogen bonding 
and π-π stacking. The design of the pH-sensitive hydrogen bonded complex takes into 
account some of the factors that can help to make it a strong and stable complex and that 
will work in polar protic solvents such as water. First, the sequences of donors and 
acceptors is an AAAA-DDDD arrangement, so it increases the number of attractive 
secondary electrostatic interactions between donor and acceptor atoms and eliminates any 
repulsive interaction between them. Second, using a hydrophilic group (triethylene 
glycol) in the acceptor molecule improves its water solubility. Also, adding functional 
groups that have electron-acceptors (oxygen atoms) to the acceptor molecule increases 
the number of the hydrogen bonds in the complex in order to form a stable self-assembly 
in polar protic solvents. 
 
 
NH2N NH2
H
NH2N NH2
Cl
pH < 6.5
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1.3.1 The design 
The design of this project has two main lines of inquiry. First, the donor and the acceptor 
molecules are going to be attached to the iron oxide nanoparticles by click chemistry 
between the alkyne group in the hydrogen bonding molecules and the azide group in the 
nanoparticles, separately and then mix them together (Figure 11) and their behavior will 
be observed with respect to aggregation in response to pH changes.  
 
Figure 11: clicking donor and acceptor molecules to SPIO nanoparticles. 
Second, the donor and the acceptor molecules are going to be attached to bifunctional 
monomers by click chemistry, between the alkyne group in the hydrogen bonding 
molecules and the azide groups in a bifunctional monomer, separately and then mix them 
together (Figure 12) and their behavior will be observed with respect to aggregation in 
response to pH changes.  
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Figure 12: clicking donor and acceptor molecules to a bifinctional monomer. 
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Chapter 2: Results and Discussion 
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2.1. Synthesis 
 
 2.1.1 Synthesis of Donor Molecule. 
 
Scheme 2: Synthesis of the donor molecule.  
2,6-diamino-3-ethynylpyridin-1-ium 4 was chosen as the DDD molecule and contains an 
alkyne functional group for eventual click chemistry to a covalent scaffold. The synthesis 
of 4 began with the iodination of commercially available, 2,6-diaminopyridine (Scheme 
2). This reaction was performed based on a previously reported synthesis 26 and was 
monitored while adding iodine dropwise over 4 hours to avoid the formation of 3,5-
diiodopyridine-2,6-diamine, since NH2 groups in positions 2 and 6 on the pyridine ring 
activate both carbons 3 and 5 for electrophilic aromatic substitution. A saturated aqueous 
solution of sodium thiosulfate was used in the workup to remove extra unreacted iodine, 
and the mixture was filtered through a celite pad to remove potassium iodide. A 57% 
yield of the monoiodo-pyridine-2,6-diamine was obtained and this yield was the best 
compared to other methods undertaken to obtain 1 and much easier. Sonogashira 
NH2N NH2 NH2N NH2
Si
NH2N NH2 NN NH
K2CO3, I2
NH2N NH2
I
THF, overnight, 
R.T.
PdCl2(PPh3)2, CuI
TEA, TMSA
overnight, R.T.
Methanol, 
2h, R.T.
1(57%) 2 (> 99%)
3 (55%)
H H
HH
pH below 6.5K2CO3
4
 	   24	  
coupling was then used to convert 1 to 2 as a first step to attach the alkyne group.27 The 
steps to produce 2 and 3 were performed very carefully using oven-dried glassware, 
deoxygenated solvents and a nitrogen atmosphere. Saturated aqueous sodium bicarbonate 
was used in the workup of the first step to neutralize the trace acid in the products and it 
gave a quantitative yield of 2. Removal of the trimethylsilyl (TMS) protecting group was 
performed using 2 equivalents of K2CO3 in methanol,28 and gave a 55 % yield after 
recrystallization.  
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2.1.2 Synthesis of Acceptor molecule. 
 
Scheme 3: Synthesis of 6. 
The synthesis of the acceptor subunit 14 began with the formation of 5 from a 
condensation between 2,6- diaminopyridine and ethyl acetoacetate in acidic conditions 
and a yield of 46% was obtained (Scheme 3).29,30 Naphthyridine 5 work up was done by 
simple dilution and neutralization in water to precipitate the product in pure form most of 
the time. For further purification, recrystallization was performed on the recovered solid 
using acetone:diethyl ether (1:1). The nucleophilic substitution to form triethylene glycol 
derivative 6 was performed by adding 1-iodo-3,6,9-trioxodecane 8 within half an hour of 
adding base and the reaction was stirred overnight.   
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N N OH2N
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Scheme 4: Synthesis of 8. 
 Iodo-3,6,9-trioxodecane 8 was synthesized to be a derivative of tri(ethylene glycol) 
bearing a good leaving group for the above described synthesis of 6 (Scheme 4). Both 
molecules 7 and 8 were prepared according to literature procedures.31,32 
 
Scheme 5: Synthesis of 12.  
The synthesis of 5-iodo-2-nitrosopyridine, 9, was initiated by iodination of 2-
aminopyridine (Scheme 5). 2 equivalents of iodine were added all at once to 2-
aminopyridine and the reaction was stirred overnight in DMF at room temperature.33 A 
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saturated aqueous solution of sodium thiosulphate was added to remove the unreacted 
iodine and to neutralize the reaction mixture.  This reaction was followed by a 
Sonogashira coupling reaction to afford 9 in a quantitative yield.34 The sulfimine 
derivative 10 was synthesized by a previously reported method with a modification of the 
reaction time to obtain higher yield. Flash column chromatography was performed using 
EtOAc as eluent to yield 58% of 11. Oxidation using 1.3 equivalent of m-
chloroperbenzoic acid (m-CPBA) at 0 °C was performed to give 12 in 75% yield after 
addition of dimethylsulfide to remove the extra unreacted m-CPBA.35,36 Workup of the 
reaction required evaporation at 20-30 °C to avoid producing a dimer. It has been shown 
in a previous study that 2-nitrosopyridine molecules exist in organic solvents as a mixture 
of the monomer and azodioxy dimer in equilibrium at room temperature.37 
 
Scheme 6: Synthesis of 13. 
After the synthesis of 12 and 6, the azo product (E)-2-(2-(2-(2-
methoxyethoxy)ethoxy)ethoxy)-4-methyl-7-((5-((trimethylsilyl)ethynyl)pyridin-2-
yl)diazenyl)-1,8-naphthyridine was synthesized from them using 1.3 equivalent of 
iodosobenzene diacetate (Scheme 6).38 Purification by column chromatography using 4% 
methanol in DCM, eluent gave 32% of 13.  
N N N OH2N
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3 N N ON
O
3
NN
Si
Si
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Scheme 7: Synthesis of the acceptor molecule, 14.  
Finally, 1 M tetra-n-butylammonium fluoride (TBAF) in THF was used to remove the 
trimethylsilyl (TMS) protecting group in 13 under dry conditions and in just 10 minutes, 
providing an 80% yield of the acceptor (Scheme 7).39 
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2.1.3 Synthesis of Dextran Coated Superparamagnetic Iron Oxide Nanoparticles 
The synthesis of water soluble SPIO nanoparticles was performed using a previously 
reported method.40 The first step involved the decomposition of FeCl2 and FeCl3 in the 
presence of ammonium hydroxide and dextran to produce water soluble dextran coated 
nanoparticles. As Weissleder and coworkers reported,6 a cross-linked dextran shell with 
amine groups ( Scheme 8) on the surface was synthesized, by using the previous 
synthesized coated nanoparticles and treating them first with epichlorohydrin and then 
aqueous ammonium hydroxide. 
 
 
 
 
Scheme 8: Synthesis of dextran-coated Fe3O4 nanoparticles. 
Dynamic light scattering (DLS) was used to measure the sizes of the particles (Figure 
13). The Z-average size was found to be 66 nm for the dextran-coated Fe3O4 
nanoparticles 15 and 77 nm for the cross-linked amine functionalized nanoparticles 16.  
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Figure 13: Size distrubution of nanoparticles 15 (gray) and 16 (dark purple).  	  	  	  
	  
	  
	  
	  
	  	  
Figure 24: UV-Vis absorbance of nanoparticles 15 (gray) and 16 (dark purple). 	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UV-Vis absorption was also performed following nanoparticle degradation with 
hydrochloric acid and hydrogen peroxide on both nanoparticles 15 and 16 to determine 
the concentration of iron.41 The calculation of concentration was based on the UV-Vis 
absorption that was found to be 3.01 at 365 nm for nanoparticles 15 corresponding to a 
concentration of 10.9 mg/mL and 1.80 at 365 nm for 16 corresponding to a concentration 
of 6.49 mg/mL.	  	  
 2.1.4 Synthesis of the linker.  
 
Scheme 9: Synthesis of the linker.  
The synthesis of the linker for attachment of the hydrogen bonding moieties to the 
nanoparticles began with a monotosylation of tri(ethylene glycol) by reaction with 0.5 
equivalents of triethylamine and 0.25 equivalents of 4-toluenesulfonyl chloride, affording 
88% of 17 (Scheme 9).42 Crude 17 was carried forward to the synthesis 2-(2-(2-
azidoethoxy)ethoxy)ethanol, 18, without any purification.43 After reaction, flash column 
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chromatography was performed on the residue using 1:1 ethyl acetate:hexane as eluent, 
affording 85% of 18. The carboxylic acid derivative 19 was synthesized by using sodium 
hydride (dispersion) as a base and alkylating the resulting oxo-anion with bromoacetate.44 
The final step to make the succinate ester linker, 20 was performed according to a 
literature procedure and afforded a similar yield.19 
2.1.5 Conjugating donor and acceptor to nanoparticles 
 
Scheme 10: Synthesis of the functionalized nanoparticles.  
The next step in order to install the azide groups on the nanoparticles, was to react linker 
20 with the cross-linked nanoparticles 16 (Scheme 10). This reaction was obtained by 
simply stirring 2.5 µmol of linker 20 per milligram of iron at a pH of 7.4 overnight in the 
dark.19 The pH was reached by performing a predialysis against 25 mM pH 7.4 citrate 
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buffer. The UV-visible absorbance was measured again following nanoparticle 
degradation with hydrochloric acid and hydrogen peroxide after performing dialysis of 
nanoparticles, 16 and for 21. The absorption was found to be 1.34 at 365 nm 
corresponding to a concentration of 4.82 mg/mL for 16 and 0.508 at 365 nm 
corresponding to a concentration of 1.83 mg/ml for 21 (Figure 15). The Z-average size of 
particles 21 was found to be 90 nm (Figure 16). In addition, the presence of the azide 
groups on the nanoparticle surface was verified using infrared (IR) spectroscopy by the 
presence of the distinctive azide stretch at 2100 cm-1 (Figure 17).  
	  
 
 
 
 
 
 
 
 
 
Figure 15: UV-Vis absorbance of nanoparticles 16 in pH 7.4 aqueous buffer (dark 
purple) and 21 (light purple).  	  	  	  	  
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
300 350 400 450 500 
A
bs
or
ba
nc
e 
Wavelength (nm)  
Nanoparticles 21 
Nanoparticles 16 
 	   34	  
 
 
 
 
 
 
 
Figure 16: Size distrubution of nanoparticles 21. 	  
 
 
 
 
 
 
 
 
 
 
Figure 17: Infrared spectra illustrating changes on nanoparticle surface. 	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azide functions on the nanoparticles (Scheme 10). The click reaction was performed 
using CuSO4 and sodium ascorbate and dissolving the donor and acceptor molecules in 
DMF with the nanoparticles. The overnight reaction was followed by dialysis against 10 
mM ethylenediaminetetraacetic acid (EDTA) to remove residual copper salts, followed 
by pure water.19 The disappearance of the peak corresponding to the azide stretch was 
verified using infrared (IR) on the nanoparticles confirming completion of the reaction 
(Figure 17). The Z-average sizes of the particles were found to be 210 nm for 22 and 110 
nm for 23 using DLS (Figure 18).  
 
 
 
 
 
 
 
Figure 18: Size distribution of nanoparticles 22 (red) and 23 (blue). 
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18).  2.1.6 Synthesis of Donor and Acceptor monomers  
 
 
 
 
 
Scheme 11: Synthesis of the PEG derivative. 
Synthesis of the PEG derivative 25 was necessary in order to do the click 
chemistry described above (Scheme 11). Synthesis of 24 was first performed by reacting 
hexa(ethylene glycol) with 6.6 equivalents of KOH and 2.5 equivalents of TsCl.45 
Recrystallization was performed to remove the mono tosylated derivatives. Compound 25 
was synthesized according to a literature procedure.46  
Donor and acceptor monomers were synthesized by click reactions (Scheme 12). 
The synthesis of the donor monomer 26 was performed by reaction between 2 equivalents 
of 3-ethynylpyridine-2,6-diamine 3 and 1 equivalent of 25, while the acceptor monomer 
27 was synthesized by reaction between 2 equivalents of (E)-7-((5-ethynylpyridin-2-
yl)diazenyl)-2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4-methyl-1,8-naphthyridine, 14 
and 1 equivalent of 25. Both click reactions were performed in the present of 0.65 
equivalents of CuI and 6.5 equivalents of 1,8-diazabicycloundec-7-ene (DBU).47 
Different workups were used for the two reactions due to the insolubility of the donor 
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monomer 26 in most organic solvents. A saturated solution of EDTA was required as a 
chelating agent to scavenge the metal ions in the workup.  
 
Scheme 12: Synthesis of the donor, 26 and Acceptor, 27 monomers. 
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2.2. pKa Titrations 
2.2.1.pKa of the Donor Molecule. 
Before starting the synthesis of 3, a weak acid-strong base titration was performed to 
determine the pKa value for the nitrogen atom in the 2,6-diaminopyridine ring. This 
titration was performed by adding 1 mL of 0.1 M NaOH to 0.1 M of 2,6-diaminopyridin-
1-ium chloride per minute and measuring the pH using a glass pH electrode at each time 
point. 2,6-Diaminopyridin-1-ium chloride was synthesized by the protonation of 2,6-
diaminopyridine with HCl (gas) that was produced by adding H2SO4 dropwise to NaCl 
(Scheme 13). Figure 19 shows the change in the pH while adding NaOH to 2,6-
diaminopyridin-1- ium chloride and from the figure, the pKa can be determined which is 
likely very similar to the pKa for 3. 
 
 
Scheme 13: synthesizing 2,6-diaminopyridin-1-ium chloride. 
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Figure 19: Weak acid-strong base titration of 2,6-diaminopyridinium chloride. 
2.2.2. pKa of the Donor Monomer. 
A weak acid-strong base titration was performed on 26 to determine the effect of the 
triazole group on the pKa of the donor. This titration was performed by adding 1 mL of 5 
x 10-4 M NaOH to 5 x 10-4 M of HCl salt of 26 per minute and measuring the pH using a 
glass pH electrode at each time point. The HCl salt of 26 was synthesized by dissolving  
26 (0.1 g) in 0.1 M HCl (2 mL) and adding it dropwise to a saturated solution of NaCl (3 
mL). Figure 20 demonstrates that the effect of adding a triazole group to the donor 
molecule changes the pKa of the donor from 6.5 to 6.  
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Figure 20: Weak acid-strong base titration of 26 HCl salt. 
 
 
 
 
 
 
 
 
 
 
 	   41	  
2.3. The Effect of Changing pH on the Aggregation of the Nanoparticles  
 The effect of changing pH on the aggregation of the nanoparticles was studied by 
measuring the Z-average size of 0.2 mg/mL nanoparticle solution (0.1 mg/mL of 22 + 0.1 
mg/mL of 23) at different pHs. The solution’s pH was altered by adding 1 x 10-3 M HCl 
and 1 x 10-3 M NaOH and the pH was measured with a pH meter. This test was also 
performed on both nanoparticles 22 and 23 alone at the same iron concentration.   
 
Figure 21: Z-average size changing with pH.  
Figure 21 shows that an increase in the Z-average size of the nanoparticle mixture started 
at pH = 6 which is the pKa of the donor molecule and reached the maximum size at 5. 
The decrease in the size after that point may be due the start of protonation of the 
naphthyridine rings in the acceptor molecule. This protonation of the acceptor is 
responsible for the Z-average size increase between 4 > pH > 3 in nanoparticle 22. 
Although having these changes, they were not significant as we expected.  
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2.4. X-ray crystallography 
An X-ray crystal structure was obtained for the acceptor 14 that explained the unexpected 
results of the aggregation tests (Figure 22). 
 
Figure 22: X-ray crystal structure of 14. 
Iodosobenzene diacetate was used to join the pyridine and naphthyridine components 
together but it was unclear whether an azo or azoxy bonds was created. MS was 
performed on the sample and showed an azo bond but it was not until this crystal 
structure was obtained that it was revealed that actually an azoxy bond was synthesized 
(N3=N4-O2). This structure also shows that TEG group was added at the nitrogen (N1) 
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instead of the oxygen (O1), a structural difference that was very difficult to elucidate by 
simple NMR spectroscopy. This improper placement blocks a hydrogen bonding site and 
disrupts the intended complexation with the donor.	  Based on the X-ray crystal structure 
of the acceptor molecule, the following revised scheme explains what happened in each 
step.  
 
Scheme 14: synthesis of the acceptor  
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2.5. 1H NMR Titration 
 An 1H NMR titration was performed between 2,6-diaminopyridinium tetrafluoroborate 
(donor) and (E)-2,4-dimethyl-7-(pyridin-2-yldiazenyl)-1,8-naphthyridine (PAN) 
(acceptor). This complex (figure 23) is structurally similar to the desired system so the 
association constant will provide insight into the strength of the proposed complex. It was 
performed in DMSO, which is a very competitive solvent, and we obtained a Ka value of 
194 M-1. 
 
Figure 23: Titration curve for complex G. 
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Chapter 3: Conclusions and Future Work 
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This thesis explored the synthesis of donor and acceptor hydrogen bonding 
moieties for conjugation to SPIO. The aim was to develop a system that would undergo 
aggregation in the mildly acidic environment of tumors, in order to provide enhanced 
contrast. Though there were a few previous examples of controlled clustering of such 
nanoparticles in the presence of stimuli, clustering induced by very small pH changes had 
not previously been demonstrated. The donor molecule was successfully synthesized in 
three simple steps including a Sonogashira coupling and deprotection of the TMS group. 
The acceptor molecule synthesis involved the preparation of an amine derivative and a 
nitroso derivative. Then, both derivatives were oxidized to obtain the azo group and 
followed by deprotection of the TMS group. SPIO were synthesized and then cross-
linked after coating them with dextran. A linker was synthesized to obtain azide group on 
the surface of the SPIO for further click reaction with the donor and acceptor molecules.  
Donor and acceptor molecules were added to azide functionalized SPIO via click 
chemistry. After conjugation to the nanoparticle surface, the results of clustering mixed 
nanoparticles within the accessible tumor pH range were not significant. The presence of 
the TEG group on one nitrogen atom in the naphthyridine ring and oxygen on the azo 
group unexpectedly was revealed by x-ray crystallography during the final stages of this 
thesis. This made the acceptor molecule too weak to form a strong complex, explaining 
the lack of SPIO clustering. However, the idea of this project may be worth carrying 
forward based on the strength of a similar complex that showed good binding strength in 
DMSO. 
 Although synthesizing non-symmetrical azo heterocyclic molecules has proven to 
be difficult, the Wisner group has recently developed a method to do so. Scheme 15 
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shows a successful route without achieving an azoxy as an intermediate and adopting this 
procedure is highly recommended for completion of this project. The PAN molecule 
(Scheme 15) was successfully synthesized by a Ph.D. candidate Jeffrey Pleizier in the 
Wisner group and the rest of the scheme is a suggested synthesis for an alternative 
acceptor molecule.48,49,50,51 
 
Scheme 15: Suggested future work. 
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Chapter 4: Experimental 
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4.1. General: 
All chemicals were of reagent quality and used as obtained from commercial sources 
unless otherwise noted. Dry solvents were obtained from an Innovative Technology SPS-
400-5 Solvent Purification System. Flasks were oven dried and nitrogen-purged prior to 
use. Reactions were carried out under an inert atmosphere (dry nirogen) unless otherwise 
indicated. Flash chromatography was performed using Silicycle pharma grade silica (40-
63µm). Dialysis was performed against water using a Spectra/Por regenerated cellulose 
membrane (12-14,000 MW cutoff). Ultrafiltration was carried out using a 300 KDa 
molecular weight cutoff (MWCO) membrane of regenerated cellulose purchased from 
Amicon. The 1H and 13C NMR data were obtained on 400 or 600 MHz spectrometers. All 
spectra were obtained in deuterated chloroform and/or DMSO-d6. The spectra were 
referenced to residual chloroform (at δ 7.25 ppm for 1H spectra and the center peak of the 
triplet at δ 77.0 (t) for 13C spectra) and DMSO-d6 (at δ 2.49 ppm for 1H spectra and the 
center peak of the multiplet at δ 39.50 (m) for 13C spectra). When peak multiplicities are 
given, the following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; EI (electron ionization) mass spectra were obtained on Finnigan MAT 8200 
and PE-Sciex API 365 mass spectrometers at an ionizing voltage of 70 eV.  
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4.2 Experimental Section  
4.2.1 Synthesis of Donor Molecule 
3-Iodo-pyridine-2,6-diamine (1). 
A suspension of 2,6-diaminopyridine (10.01 g, 0.091 mol) and 
potassium carbonate (12.65 g, 0.091 mol) in THF (100 mL) was 
stirred for 1 hour. A solution of iodine (23.3 g, 0.091 mol) in THF 
(50 mL) was added dropwise over 4 hours to the suspension. The reaction mixture was 
stirred overnight at room temperature. After the reaction time, the resulting residue was 
filtered through a celite pad and the filtrate was washed with water and a saturated 
aqueous solution of sodium thiosulphate to remove the extra-unreacted iodine. The 
organic layer was dried over potassium carbonate and evaporated under reduced pressure 
affording a gray solid of the title compound 1 (12.24 g, 57 %). 1H NMR (CDCl3, 400 
MHz): δ 4.22 (s, 2H), 4.68 (s, 2H), 5.72 (d, 1H, J=8.2), 7.50 (d, 1H, J=8.2). 13C NMR 
(400 MHz, CDCl3): δ 61, 100.5, 147.9, 156.3, 157.6. HRMS calcd for C5H6IN3 [M]+: 
234.9606, found: 234.9607.  
 3-(Trimethylsilyethynyl) pyridine-2,6-diamine (2). 
3-Iodo-pyridine-2,6-diamine (1, 12.0 g, 51.0 mmol), 
PdCl2(PPh3)2 ( 0.35 g, 0.51 mmol, 1.0 mol %), and CuI ( 0.19 g, 
0.99 mmol, 2.0 mol %) were charged in an oven-dried, nitrogen-
purged 250 mL round bottom flask under N2 atmosphere. Triethylamine (100 mL) which 
was deoxgenated by being bubbled with N2 gas for 30 mintues was added via syringe 
followed by the addition of TMSA (5.99  g, 61.01 mmol). The reaction stirred overnight 
NH2N NH2
I
NH2N NH2
Si
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under N2 at room temperature. After reaction time, solvent was removed under reduced 
pressure. Saturated aqueous sodium bicarbonate (50 mL) was added to the residue and 
chloroform (100 mL). The mixture was further extracted with chloroform (3 x 20 mL). 
The combined organic layers were dried over potassium carbonate and evaporated under 
reduced pressure to obtain dark brown solid of the titled compound 2 (10.4 g, 100%). 1H 
NMR (CDCl3, 400 MHz): δ 0.23 (s, 9H), 4.36 (s, 2H), 4.82 (s, 2H), 5.81 (d, 1H, J=8.2), 
7.31 (d, 1H, J=8.2). 13C NMR (400 MHz, CDCl3): δ 0.13, 97.7, 98, 101.7 141.9, 157.4, 
159.2. HRMS calcd for C10H15N3Si [M]+: 205.1035, found: 205.1037.  
 3-Ethynylpyridine-2,6-diamine (3).  
To 3-(trimethylsilyethynyl) pyridine-2,6-diamine (2, 10.4 g, 50.65 
mmol) and potassium carbonate ( 13.99 g, 101.3 mmol), methanol 
(100 mL) which was deoxgenated by being bubbled with N2 gas for 
30 mintues was added under N2. The reaction solution stirred for 2 hours at room 
temperature. After reaction, the solution was evaporated under reduced pressure and the 
remaining residue was dissolved in chloroform and diluted with water. Extraction was 
performed with chloroform (3 x 50 mL). The combined organic layers were dried over 
potassium carbonate and evaporated under reduced pressure to afford (3.6 g, 55%) of the 
donor molecule after recrystallization using chloroform: hexane. 1H NMR (CDCl3, 400 
MHz): δ 3.31 (s, 1H), 4.36 (s, 2H), 4.81 (s, 2H), 5.84 (d, 1H, J=8.2), 7.34 (d, 1H, J=8.2). 
13C NMR (400 MHz, CDCl3): δ 80.5, 81.1, 97.8, 142.3, 157.6, 159.5. HRMS calcd for 
[M]+ calc’d for C7H7N3: 133.0640, found: 133.0643 
 
NH2N NH2
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4.2.2 Synthesis of Acceptor Molecule.  
 7-Amino-2-hydroxy-4-methyl-1,8-naphthyridine (5).   
 2,6-Diaminopyridine (32.74 g, 300.01 mol) and ethyl 
acetoacetate (39.05 g, 300.01 mol) were heated in phosphoric 
acid (130 mL) for 3 hour at 110 °C. After cooling to room 
temperature, the solution was poured into distilled water and neutralized by adding 
ammonium hydroxide until pH: 7 and filtered affording a beige solid (24.03 g, 45.6 %) of 
the titled product 5. 1H NMR (DMSO, 400 MHz): δ 2.27 (s, 3H), 5.99 (s, 1H), 6.33 (d, 
1H, J=8.6), 6.66 (s, 2H), 7.69 (d, 1H, J=8.6). HRMS calcd for C9H9N3O [M]+: 175.0746, 
found: 175.0748. 
 Functionalized Naphthyridine (6).  
To 7-amino-2-hydroxy-4-methyl-1,8-naphthyridine (5, 1.02 g, 5.8 
mmol ) in DMSO (50 mL), 60 % sodium hydride (0.23 g, 5.8 
mmol) was added to the solution carefully under N2. After 30 
minutes, 1-iodo-3,6,9-trioxodecane (8, 1.58 g, 5.8 mmol) was 
added via syringe and reaction stirred overnight under N2 at room temperature. After 
reaction time, the solution was poured into distilled water and extracted many times with 
dichloromethane. The organic layers were combined and washed with distilled water and 
dried over potassium carbonate. The solvent was removed by rotary evaporation 
affording a brown oil (1.17 g, 62.9 %) of the titled product 6. 1H NMR (CDCl3, 400 
MHz): δ 2.31 (s, 3H), 3.36 (s, 3H), 3.51-3.53 (m, 2H), 3.60-3.63 (m, 4H), 3.70-3.72 (m, 
2H), 3.75 (t, 2H, J=6.6), 4.63 (t, 2H, J=6.6) 4.97 (s, 2H), 6.29 (s, 1H), 6.36 (d, 1H, 
N NH OH2N
N N OH2N
O
3
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J=8.6), 7.66 (d, 1H, J=8.6). 13C NMR (400 MHz, CDCl3): δ 17.9, 39, 58.5, 67.4, 69.7, 
69.9, 71.4, 103.9, 107.4, 115.1, 134.3, 145.7, 149, 158.6, 162.8. HRMS calcd for 
C16H23N3O4 [M]+: 321.1689, found: 321.1685.  
 1-(p-Tolysulfonyl)-3,6,9-trioxodecane (7).  
To sodium hydroxide (5.72 g, 80.0 mmol) in water 
(20 mL), tri(ethylene glycol) monomethyl ether 
(13.26 g, 80.0 mmol) in dry THF (20 mL) was added under N2. The flask was cooled in 
an ice bath with stirring and a solution of 4-toluenesulfonyl chloride (15.28 g, 80.0 
mmol) in THF (24 mL) was added dropwise over 30 minutes. After addition, the reaction 
stirred under N2 at room temperature overnight. After the reaction time, distelled water 
was added to the residue and was neutralized using sulfuric acid and solution was 
extracted many times with DCM. The combined organic layers were washed with 
distilled water and dried over potassium carbonate. The organic layer was evaporated 
under reduced pressure affording a clear colorless oil of the title product 7 (23.67 g, 92.9 
%). 1H NMR (CDCl3, 400 MHz): δ 2.21 (s, 3H), 3.12 (s, 3H), 3.27-3.29 (m, 2H), 3.34 (s, 
4H), 3.35-3.38 (m, 2H), 3.44 (t, 2H, J=4.3), 3.93 (t, 2H, J=4.3), 7.14 (d, 2H, J=8.2), 7.56 
(d, 2H, J=8.2); 13C NMR (400 MHz, CDCl3): δ 20.7, 58.0, 67.8, 68.7, 69.6, 69.8, 71, 
127.1, 129.1, 132.2, 144.1. HRMS calcd for C14H22O6S [M]+: 318.1137, found: 318.1132.  
 1-Iodo-3,6,9-trioxodecane (8). 
1-(p-Tolysulfonl)-3,6,9-trioxodecane, 7 (10.0 g, 
31.4 mmol) and sodium iodide (9.9 g., 66.0 mmol) 
were dissolved in acetone (80 mL) and refluxed overnight under N2. After reaction, the 
O O O O
Ts
OOOI
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solution was filtered. After the evaporation of solvent, the residue was diluted with DCM. 
The organic layer was washed with aqueous sodium thiosulfate then brine (2 x each) and 
dried over sodium sulfate. The organic layer was removed by rotary evaporation 
affording a yellowish oil (6.9 g, 80.2 %) of the titled product 8. 1H NMR (CDCl3, 400 
MHz): δ 2.99 (t, 2H, J=6.8), 3.09 (s, 3H), 3.25-3.27 (m, 2H), 3.35-3.38 (m, 6H), 3.48 (t, 
2H, J=6.8); 13C NMR (400 MHz, CDCl3): δ 2.7, 58.6, 69.8, 70.19, 70.2, 71.54, 71.55. 
HRMS calcd for C7H15IO3 [M]+: 274.0066, found: 274.0153 
5-Iodo-2-aminopyridine (9). 
To 2-aminopyridine (20.0 g, 212.0 mmol) in DMF (200 mL), iodine 
(53.8 g, 424.0 mmol) was added and the mixture was stirred 
overnight at room temperature. The resulting mixture was poured 
into another mixture of 12 g sodium metabisulfate in 120 mL ammonium hydroxide and 
aqueous sodium thiosulphate. The product was extracted many times with DCM and the 
combined organic layers were dried using MgSO4 and evaporated under reduced 
pressure. The resulting residue was recrystallized using DCM: Hexane. The resulting 
golden solid was filtered and air dried to afford (14.0 g, 30 %) of the compound 9. 1H 
NMR (CDCl3, 400 MHz): δ 4.45 (s, 2H), 6.36 (d, 1H, J=8.6), 7.63 (d, 1H, J=8.6), 8.23 (s, 
1H). 13C NMR (400 MHz, CDCl3): δ 77.7, 110.8, 145.2, 153.7, 157.2. HRMS calcd for 
C5H5IN2 [M]+: 219.9497, found: 219.9506.  
 
 
N
I
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5-((Trimethylsilyl)ethynyl)pyridin-2-amine (10).  
 5-Iodo-2-aminopyridine (9, 12,7 g, 57.8 mmol), PdCl2(PPh3)2 ( 
0.4 g,  0.57 mmol, 1.0 mol %), and CuI ( 0.22 g,  1.1 mmol, 2.0 
mol %) were charged in an oven-dried, nitrogen-purged 250 mL 
round bottom flask under N2 atmosphere. Triethylamine (150 mL) which was 
deoxgenated by being bubbled with N2 gas for 30 mintues was added via syringe 
followed by the addition of TMSA (6.8 g, 69.2 mmol). The reaction was stirred at room 
temperature overnight under N2. After the reaction time, solvent was then removed under 
reduced pressure. Saturated aqueous sodium bicarbonate (50 mL) was added to the 
residue and chloroform (100 mL). The mixture was further extracted with chloroform (3 
x 50 mL). The combined organic layers were dried over potassium carbonate and 
evaporated under reduced pressure to obtain a brownish solid (10.9 g, 100%) of the title 
product 10. 1H NMR (CDCl3, 400 MHz): δ 0.21 (s, 9H), 4.77 (s, 2H), 6.41 (d, 1H, J= 
8.6), 7.46 (d, 1H, J= 8.6), 8.18 (d, 1H). 13C NMR (400 MHz, CDCl3): δ 0, 94.4, 102.7, 
107.7, 109.6, 140.6, 151.8, 157.5. HRMS calcd for C10H14N2Si [M]+: 190.0926, found: 
190.0930.  
5-((Trimethylsilyl)ethynyl)pyridin-2-sulfimine (11). 
 To 5-((trimethylsilyl)ethynyl)pyridin-2-amine (10, 8.24 g, 43.3 
mmol) and dimethyl sulfide (3.2 g, 52.0 mmol) in DCM (150 
mL) , n-chlorosuccinimide (8.6 g, 65.0 mmol) in DCM (100 
mL) was added dropwise over 2 hours while the temperature has maintained at 0 °C. 
After addition, the mixture was stirred for 2 hours at 0 °C and for an additional 2 hours at 
N
Si
NH2
N
Si
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room temperature. A solution of sodium methoxide (4.2 g, 78.0 mmol) in methanol (20 
mL) was then added to the mixture. After 15 minutes, water (100 mL) was added to the 
reaction mixture and stirred overnight at room temperature. After reaction time, the 
organic layer was separated and the aqueous layer was extracted with DCM. The 
combined organic layers were dried over MgSO4. The solvent was removed by roto-
evaporation and flash column chromatography was performed using EtOAc as eluent 
system. The product was obtained in the form of brown oil (6 g, 55%). 1H NMR (CDCl3, 
400 MHz): δ 0.17 (s, 9H), 2.76 (s, 6H), 6.57 (d, 1H, J= 8.6), 7.36 (d, 1H, J= 8.6), 8.08 (s, 
1H). 13C NMR (400 MHz, CDCl3): δ -0.3, 32.5, 93.9, 103.1, 107.4, 112.8, 139.4, 150.4, 
162.3. HRMS calcd for C12H18N2SSi [M]+: 250.0960, found: 250.0967.  
2-Nitroso-5-((trimethylsilyl)ethynyl)pyridine (12).  
To 5-((trimethylsilyl)ethynyl)pyridin-2-sulfimine (11, 5.5 g, 22.0 
mmol) in DCM (20 ml), meta-chloroperoxybenzoic acid (70-
75%, 9.2 g, 33.0 mmol) in DCM (50 mL) was added dropwise 
over 10 minutes while temperature was maintained at 0 °C. After addition, the reaction 
mixture was stirred for 3 hours at 0 °C. Dimethyl sulfide (1.3 g, 22.0 mmol) was then 
added to the reaction and the mixture was allowed to warm up to room temperature and 
stirred for an additional 1 hour. After reaction time, a saturated solution of sodium 
carbonate was added and the organic layer was separated. The aqueous layer was 
extracted with DCM (2 x 30 mL). The organic solvent was removed by rotary 
evaporation at low temperature 20-30 °C to avoid getting more of the dimer molecule 
affording a brownish solid (3.4 g, 75%) of the monomer and dimer of the title compound 
12. 1H NMR (CDCl3, 400 MHz): δ (monomer) 0.29 (s, 9H), 7.29 (d, 1H, J= 8.6), 7.94 (d, 
N
Si
N O
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1H, J= 8.6), 8.82 (s, 1H): δ (dimer) 0.25 (s, 9H), 7.79 (d, 1H, J= 8.6), 8.05 (s, 1H), 8.06 
(d, 1H, J= 8.6). 
 Acceptor (13).  
To (6, 4.0 g, 12.4 mmol) and (12, 2.5 g, 12.4 
mmol) in DCM (100 mL), iodosobenzene 
diacetate (5.2 g, 16.0 mmol ) was added and the 
reaction mixture stirred overnight under N2 at 
30 °C. After reaction time, the solvent was 
removed by roto-evaporation. Column chromatography was performed using 4% 
methanol in DCM as eluent system affording a dark brown oil (2.1 g, 32%). 1H NMR 
(CDCL3, 400 MHz): δ 0.26 (s, 9H), 2.43 (s, 3H), 3.28 (s, 3H), 3.42-3.44 (m, 2H), 3.51-
3.55 (m, 4H), 3.68 (t, 2H), 3.79 (t, 2H, J=6.6), 4.7 (t, 2H, J=6.6), 6.6 (s, 1H), 7.88 (d, 1H, 
J=8.2), 8.02 (d, 1H, J=8.6), 8.08 (d, 1H, J=8.2), 8.33 (d, 1H, J=8.6), 8.68 (s, 1H). 13C 
NMR (400 MHz, CDCl3): δ -0.4, 18.2, 58.9, 67.7, 70, 70, 70.2, 70.5, 71.2, 71.7, 71.8, 
99.6, 102.9, 112.5, 116.6, 117.2, 122,4, 124.5, 135.1, 142, 144.7, 149, 151.2, 155.3, 
162.6. HRMS calcd for C26H33N5O5Si [M]+: 523.2251, found: 507.2005.  
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Acceptor (14).  
To (13, 1.24 g, 2.4 mmol) in dry THF (10 mL), 1 M 
TBAF (3 mL) was added to the reaction with cooling in 
an ice bath under N2. After addition, the reaction 
mixture was allowed to stir for 10 minutes at room 
temperature. After the reaction, water was added to the mixture and extracted using ethyl 
acetate. The combined organic layers were dried over sodium sulphate and evaporated 
under reduced pressure. Flash column was perform for further purification using ethyl 
acetate as eluent system to afford brown solid (0.8 g, 80%) of the acceptor. 1H NMR 
(CDCl3, 400 MHz): δ 2.45 (s, 3H), 3.31 (s, 1H), 3.36 (s, 3H), 3.53-3.56 (m, 2H), 3.61-
3.67 (m, 4H), 3.74 (t, 2H), 3.82 (t, 2H, J=6.6), 4.73 (t, 2H, J=6.6), 6.63 (s, 1H), 7.92 (d, 
1H, J=8.2), 8.08 (d, 1H, J=8.6), 8.10 (d, 1H, J=8.2), 8.37 (d, 1H, J=8.6), 8.75 (s, 1H). 13C 
NMR (400 MHz, CDCl3): δ 18, 58.7, 67.6, 69.7, 69.8, 70, 70.3 71, 71.5, 71.6, 112.3, 
116.4, 117.1, 122.3, 123.3, 134.8, 142.1, 144.4, 148.9, 151.2, 155.1, 155.4, 162.4. HRMS 
calcd for C23H25N5O5 [M]+: 451.1856, found: 435.18212.  
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4.2.3 Iron Oxide Nanoparticles Synthesis 
Dextran-coated Fe3O4 nanoparticles (15). 
 To FeCl3·6H2O (0.15g, 0.56 mmol), FeCl2·4H2O (0.064g, 0.32 mmol) 
and dextran (70 K, 1 mL) dissolved in water (2 mL), NH4OH (7.5%, 1 
mL) was added dropwise over 10 minutes while stirring. This mixture was 
then warmed to 70˚C.  After 15 min, the mixture was cooled to room temperature and 
water (10 mL) was added. The mixture then was centrifuged three times at 4000 rpm for 
15 min.  Finally, ultrafiltration was performed 6 times to remove excess dextran and 
reduce the volume.  
Iron concentration for nanoparticles 15 = 10.88 mg/mL 
Cross-linked amine functionalized nanoparticles (16). 
 To dextran-coated Fe3O4 nanoparticle (4.0 mL, 10.88 mg/mL), 
NaOH solution (6.54 mL, 5 M) was added under inert atmosphere. 
After stirring at room temperature for 15 min, Epichlorohydrin 
(2.67 mL) was then added dropwise to the reaction mixture.. After 
8 h, NH4OH solution (4 mL, 30%) was added and the mixture was stirred vigorously 
overnight.  Dialysis in a regenerated cellulose membrane (12-14 K) against sodium citrate 
solution (0.025M) was then performed to remove excess starting materials, followed by 
ultrafiltration to reduce the volume.  
Iron concentration for nanoparticles 16 = 6.49 mg/mL  
 
Fe3O4 
H2N
H2N
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4.2.4 Synthesis of Linker  
2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (17). 
 To triethylene glycol (12.0 g, 80.0 mmol), 
triethylamine (4.0 g, 40.0 mmol) in dichloromethane 
(100 mL), 4-toluenesulfonyl chloride (3.8 g, 20.0 mmol) was added. The mixture was 
stirred at room temperature. After 12 hours, the mixture was washed with 1 M potassium 
bisulfate and 5% sodium bicarbonate and the organic layer was separated and 
concentrated under reduced pressure providing a colorless oil of the crude product (5.3 g, 
22%) which was used for the next reaction without any further purification. 1H NMR 
(400 MHz, CDCl3): δ 2.27 (s, 3H), 3,29 (s, 1H), 3.38 (t, 2H), 3.41 (s, 4H), 3,52 (t, 4H), 
3,99 (t, 2H), 7.20 (d, 2H, J=8.2 Hz), 7.62 (d, 2H, J=8.2 Hz). 13C NMR (400 MHz, 
CDCl3): δ 21, 60.9, 67.9, 68.8, 69.5, 70, 72, 127.3, 129.4, 132.2, 144.4. HRMS calcd for 
C13H20O6S [M]+: 304.0981, found: 304.8603.  
2-(2-(2-Azidoethoxy)ethoxy)ethanol (18). 
 To a solution of 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 
4-methylbenzenesulfonate (17, 4.0 g, 13.0 mmol) in 
DMF (50 mL), sodium azide (1.7 g, 26.0 mmol ) was added. The mixture was stirred 
overnight at room temperature. After the reaction time, the mixture was poured into water 
and extracted with DCM (3 x 50 mL). After washing the organic layer with brine (4 x 
100 mL), it was dried over MgSO4 and solvent was removed under reduced pressure. 
Flash column chromatography was perform on the crude, using ethyl acetate: Hexane 
(1:1) as eluent system which afforded a colorless liquid (2.2 g, 97%) of the title 
HO O O O Ts
O O N3HO
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compound. 1H NMR (CDCl3, 400 MHz): δ 3.34 (t, 2H), 3.54 (t, 2H), 3.61-3.63 (m, 6H), 
3.65-3.68 (m, 2H). 13C NMR (400 MHz, CDCl3): δ 49.9, 60.6, 69.2, 69.5, 69.8, 72.  
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)acetic acid (19). 
 2-(2-(2-azidoethoxy)ethoxy)ethanol (18, 1.2 g, 7.0 
mmol) and bromoacetic acid ( 0.98 g, 7.0 mmol) 
were dissolved in dry THF (20 mL). 60% Sodium hydride (0.78 g, 16.0 mmol) was added 
under N2 and the mixture was refluxed for 24 hours. After the reaction time, the solvent 
was evaporated and the residue was stirred with 2 M HCl for 3 hours. The mixture was 
then extracted with dichloromethane (3 x 20 mL). The combined organic layers were 
dried over MgSO4 and evaporated under reduced pressure. Column chromatography 
using 100% ethyl acetate as eluent system gave a yellowish oil (1.0 g, 62 %). 1H-NMR 
(CDCl3, 400 MHz): δ 3.38 (t, 2H), 3.64-3.7 (m, 8H), 3.73-3.75 (m, 2H), 4.16 (s, 2H). 13C 
NMR (400 MHz, CDCl3): δ 50, 67.8, 69.4, 69.9, 70, 70.1, 70.2,172.5. HRMS calcd for 
C8H15N3O5 [M]+: 234.1012, found: 234.1091.  
Water soluble linker (20).  
  To (19, 0.50 g, 2.2 mmol), N-
hydroxysuccinimide (0.25 g, 2.2 mmol) and 
DCC (0.47 g, 2.3 mmol) were added under 
inert atmosphere and dissolved in 20 mL of anhydrous acetonitrile. The mixture stirred 
for 6 hours at 65 °C. After the reaction time, the residue was cooled to room temperature 
and filtered to remove byproducts and the solvent was evaporated under reduced pressure 
to afford a colorless oil (0.7 g, 96%) of the corresponding product. 1H NMR (400 MHz, 
O O O N3HO
O
O O O N3O
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CDCl3): δ 2.84 (s, 4H), 3.38 (t, 2H), 3.64-3.71 (m, 8H), 3.77-3.79 (m, 2H), 4.51 (s, 2H). 
13C NMR (400 MHz, CDCl3): δ 169.2, 166.3, 71.5, 70.8, 70.2, 66.7, 50.9, 25.8. 
Conjugation of Linker (20) and Nanoparticles (16), synthesis of nanoparticles (21). 
  A dialysis was performed against 25 mM pH 7.4 citrate buffer to 
transfer nanoparticles 16 from pure water to buffer. The linker 20 
(16.0 mg, 50.0 µmol) in 0.25 mL of 1:1 DMSO/ H2O then was 
added to a solution of nanoparticle 16 (10.0 mg of Fe) in 2.1 mL. 
The solution was stirred overnight in the dark. The resulting solution was then dialyzed 
against pure water for 24 hours to afford nanoparticles 21.  
Iron concentration of nanoparticles 16 after the dialysis = 4.82 mg/mL. 
Iron concentration for nanoparticles 21 = 1.83 mg/mL  
Conjugation of Donor (3) and Acceptor (14) to Nanoparticle (21), Synthesis of 
Nanoparticles (22) and (23).  
 To nanoparticle 17 (1.8 mg of Fe in 1 mL of 
water) was added the donor, 3 (2.6 mg, 20.0 µmol, 
2.0 equivalent per azide) or the acceptor, 14 (8.7 
mg, 20.0 µmol, 2.0 equivalent per azide) dissolved in DMF (0.5 mL) under inert 
atmosphere. Sodium ascorbate (8 mg, 40.0 µmol) and CuSO4 (2.4 mg, 10.0 µmol) were 
then added and the mixture was stirred overnight. A dialysis was then performed against 
10 mM EDTA, followed by pure water.  
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Iron concentration of nanoparticles 22 after the dialysis = 1.11 mg/mL.  
Iron concentration of nanoparticles 23 after the dialysis = 0.58 mg/mL.  
4.2.5 Synthesis of the PEG derivative.  
3,6,9,12,15-Pentaoxaheptadecane-1,17-diol, 1,17-bis(4-methylbenzenesulfonate) (24).  
 To hexa(ethylene glycol) (7.0 g, 25.0 mmol) and p-toluenesulfonyl 
chloride (14.2 g, 75.0 mmol) in dry THF (200 mL), potassium 
hydroxide (9.3 g, 165.0 mmol) in water (50 mL) was added dropwise over 10 minutes 
while cooling in an ice bath. After addition, the reaction was stirred under N2 at room 
temperature for 36 hours. The solution was then poured into water and neutralized with 
sulfuric acid and extracted many times with DCM. The combined organic layers were 
then washed with distilled water and dried over potassium carbonate. The organic layer 
was evaporated under reduced pressure, and the product was recrystallized from hexane 
to afford the corresponding product 24 (13.2 g, 90%). 1H NMR (CDCl3, 400 MHz): δ 
2.26 (s, 6H), 3.39 (s, 8H), 3.44 (s, 8H), 3.50 (t, 4H, J=4.6), 3.98 (t, 4H, J=4.6), 7.19 (d, 
4H, J=8.2), 7.61 (d, 4H, J=8.2); 13C NMR (400 MHz, CDCl3): δ 20.9, 67.9, 68.8, 69.9, 
127.2, 129.3, 132.3, 144.3. HRMS calcd for C26H38O11S2 [M]+: 590.1856, found: 
590.1832.  
1,17-Diazido-3,6,9,12,15-pentaoxaheptadecane (25).  
 To (24, 12.0 g, 20.0 mmol) in DMF (250 mL), sodium azide (5.3 
g, 80.0 mmol) was added. The mixture was stirred for 2 days at 
room temperature under N2. The mixture was then filtered through a thin Celite bed and 
N3
ON3 5
Ts O O Ts6
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the filtrate was poured into a lot of distilled water and extracted many times with 
chloroform. The combined organic layers were washed (2 x) with distilled water and then 
dried over MgSO4. Solvent was removed by rotary evaporation affording an orange oil 
(6.68 g, 99%) of the diazide. 1H NMR (CDCl3, 400 MHz): δ 3.24 (t, 4H), 3.51 (s, 8H), 
3.52 (s, 8H), 3.53 (t, 4H). 13C NMR (400 MHz, CDCl3): δ 50.1, 69.5, 70.1. HRMS calcd 
for C12H24N6O5 [M]+: 332.1808, found: 332.1887.  
4.2.6 Synthesis of Donor and Acceptor Monomers.  
Donor Monomer (26).  
To 3-ethynylpyridine-2,6-diamine (3,  2.0 
equivalents, 0.4 g, 3.0 mmol) and1,17-diazido-
3,6,9,12,15-pentaoxaheptadecane (25, 1.0 equivalent, 
0.49 g, 1.5 mmol) in Toluene (20 mL), CuI ( 0.65 
equivalent, 0.18 g, 0.96 mmol) and DBU (6.5 equivalents, 1.5 g, 9.6 mmol) were added 
under N2. The reaction mixture was stirred for 2 hours under N2 at 70 °C. The solvent 
was then removed and the crude product washed with ethyl acetate, CH2Cl2, and THF 
affording a brown solid (0.3 g, 33%) of monomer 26. 1H NMR (DMSO, 400 MHz): δ 
3.42 (s, 4H), 3.45-3.47 (m, 4H), 3.5-3.51 (m, 4H), 3.59 (t, 4H), 3.83 (t, 4H), 4.51 (t, 4H), 
5.67 (s, 4H), 5.77 (d, 2H, J=8.2), 6.49 (s, 4H), 7.45 (d, 2H, J=8.2), 8.25 (s, 2H). HRMS 
calcd for C26H38N12O5 [M]+: 598.3088, found: 598.3109.  
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Acceptor Monomer (27).  
To of (E)-7-((5-ethynylpyridin-2-yl)diazenyl)-
2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4-
methyl-1,8-naphthyridine (14, 2.0 equivalents, 
0.5 g, 12.0 mmol) and 1,17-diazido-
3,6,9,12,15-pentaoxaheptadecane (25, 1.0 
equivalent, 0.2 g, 0.6 mmol) in Toluene (20 
mL), CuI ( 0.65 equivalent, 0.075 g, 0.39 
mmol) and DBU (6.5 equivalents, 0.6 g, 3.9 mmol) were added under nitrogen. The 
reaction mixture stirred for 2 hours under N2 at 70 °C. After reaction time, the solvent 
was concentrated using reduced pressure and the resulting crude was dissolved in DCM 
and washed with a saturated aqueous solution of EDTA and then water. The organic layer 
was dried over MgSO4 and evaporated affording yellowish oil (0.1 g, 14%) of monomer 
27. 1H NMR (CDCl3, 400 MHz): δ 2.46 (s, 6H), 3.31 (s, 6H), 3.45-3.48 (m, 4H), 3.54-
3.58 (m, 8H), 3.6-3.65 (m, 16H), 3.71 (t, 4H), 3.83 (t, 4H), 3.94 (t, 4H), 4.65 (t, 4H), 4.75 
(t, 4H), 6.63 (s, 2H), 7.92 (d, 2H, J=8.2), 8.11 (d, 2H, J=8.2), 8.34 (s, 2H), 8.46 (d, 2H, 
J=8.6), 8.55 (d, 2H, J=8.6), 9.10 (s, 2H). 13C NMR (400 MHz, CDCl3): δ 18.2, 50.5, 
58.9, 67.8, 69.2, 69.9, 70, 70.4, 70.45, 70.5, 70.54, 70.6, 71.8, 112.5, 116.5, 116.7, 118, 
122.5, 122.8, 130.8, 131.1, 134.9, 135.8, 142.8, 144.5, 145.5, 149.2, 162.6.  
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